A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder.

PHASE3CompletedINTERVENTIONAL

Enrollment

495

Participants

Timeline

Start Date

January 29, 2014

Primary Completion Date

February 8, 2018

Study Completion Date

February 17, 2018

Conditions

Bipolar I Disorder

Interventions

DRUG

SM-13496

Trial Locations (8)

Japan 68 sites, Tokyo

Lithuania 3 sites, Kaunas

Malaysia 5 sites, Kuala Lumpur

Philippines 5 sites, Manila

Russia 19 sites, Moscow

Slovakia 5 sites, Žilina

Taiwan 8 sites, Taipei

Ukraine 9 sites, Kiev

All Listed Sponsors

lead

Sumitomo Pharma Co., Ltd.

INDUSTRY

NCT01986114 - A Long-Term Study of SM-13496 in Patients With Bipolar I Disorder. | Biotech Hunter | Biotech Hunter